
AI Sight Limited is a UK-based company that commercializes a next-generation AI system for diabetic retinal screening. Their flagship product, AI-Sight, is a highly sensitive, specific, and low-cost web-based diagnostic tool designed to provide WHO-recommended diabetic eye screening services globally. The system interprets images across diabetic retinopathy disease severity and treatment intervention points, uniquely offering an indication of certainty in its grading by identifying borderline and contentious cases for human assessment. This feature addresses adoption hesitancy and differentiates AI-Sight from other AI diagnostic tools, which are often cumbersome, time-consuming, and require expensive retraining. The company is led by a team of world-leading researchers, clinicians, and healthcare experts, and has spun out from the University of Liverpool. AI Sight targets markets with significant unmet needs, including over 180 countries lacking diabetic retinopathy screening programs, aiming to reduce the leading cause of working-age blindness worldwide.

AI Sight Limited is a UK-based company that commercializes a next-generation AI system for diabetic retinal screening. Their flagship product, AI-Sight, is a highly sensitive, specific, and low-cost web-based diagnostic tool designed to provide WHO-recommended diabetic eye screening services globally. The system interprets images across diabetic retinopathy disease severity and treatment intervention points, uniquely offering an indication of certainty in its grading by identifying borderline and contentious cases for human assessment. This feature addresses adoption hesitancy and differentiates AI-Sight from other AI diagnostic tools, which are often cumbersome, time-consuming, and require expensive retraining. The company is led by a team of world-leading researchers, clinicians, and healthcare experts, and has spun out from the University of Liverpool. AI Sight targets markets with significant unmet needs, including over 180 countries lacking diabetic retinopathy screening programs, aiming to reduce the leading cause of working-age blindness worldwide.
Product: Web-based, camera-agnostic AI system for diabetic retinopathy screening that grades disease severity and flags borderline/contentious cases for human review.
Origin & location: University of Liverpool spin-out based at The Innovation Centre, Sci‑Tech Daresbury, Cheshire, England (Company Reg. 14370887).
Clinical focus: Automated retinal image analysis to detect referable diabetic retinopathy and support clinical workflows.
Funding status: Seed round announced 2024-09-19; amount undisclosed; investors listed include Deepbridge Capital, Pitalia, Phil Kirby, Michael Bibby.
Diabetic retinopathy screening and detection of referable diabetic eye disease.
2022
Healthtech
Investors listed for the round include Deepbridge Capital, Pitalia, Phil Kirby and Michael Bibby; amount was not disclosed in public company-data entries.
“Seed round announced 2024-09-19 with investors listed including Deepbridge Capital, Pitalia, Phil Kirby and Michael Bibby. Company reports start-up capital from the University of Liverpool Enterprise Investment Fund and states it is actively raising further investment.”